Oral phosphate, calcitriol; in the event of severe bowing, an osteotomy may be performed to correct the leg shape. The monoclonal antibody Burosumab was first licensed in February 2018 by the European Medicines Agency, then licensed by the Food and Drug Administration in the United States of America in June 2018 as the first drug targeting the underlying cause for this condition. The leg deformity can be treated with Ilizarov frames and CAOS. It is also treated with medications including human growth hormone, calcitriol, and phosphate.
X-linked hypophosphatemia
Autosomal dominant hypophosphatemic rickets
Pseudohypoparathyroidism
X-linked recessive hypoparathyroidism
Eruptive hypomelanosis
Hypoparathyroidism
Malignant infantile osteopetrosis
Pseudopseudohypoparathyroidism